Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials

• 主要な著者: Lin Fan (著者), Yuanyuan Zhang (著者), Peter Maguire (著者), Dominic Muston (著者), Matthew Monberg (著者), Jagadeswara Rao Earla (著者), Adela Mihai (著者), Poonam Gulati (著者)
• フォーマット: 図書
• 出版事項: Taylor & Francis Group, 2022-12-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Background The economic impact of adverse events (AEs) for poly (ADP-ribose) polymerase inhibitors (PARPis) in ovarian or breast cancer has not been widely evaluated.Objective Compare PARPi-related AE management costs from a US payer perspective.Methods The frequency of treatment-related grade 3-4 A...